[1561]
Premalignant Evolution of Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1562]
Radiologic Evaluation in Lung Cancer
[149,0 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1563]
The Role of Radiotherapy in Non-Small Cell Lung Cancer
[153,6 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1564]
Prevention of Lung Cancer
[98,4 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1565]
Women and Lung Cancer
[176,3 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1566]
Invasion Beyond Interlobar Pleura in Non-small Cell Lung Cancer
[157,5 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1567]
Cigarette Smoking and Histologic Type of Lung Cancer in Men
[163,3 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1568]
Intrapulmonary Satellite Nodule of Lung Cancer as aT Factor
[157,8 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1569]
Progression of Asbestosis Predicts Lung Cancer
[160,3 KB]
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1570]
Prolonged Survival After Extracranial Metastasectomy From ...
[23,4 KB]
From [www.annalssurgicaloncology.org] Last viewed: 07.08.2004
lung
cancer
PET scanning for staging of Non- Small Cell Lung Cancer
Giancarlo Pillot
12 Sep 2003
Talk Overview
Background Statistics
Staging Overview
Traditional Staging methods
Clinical Exam and history
CXR
CT Chest
Surgical Staging
Talk Overview
PET scanning
Physics
Staging Trials
"Preoperative Staging of Non- Small Cell Lung Cancer with PET"
Co- registered images trial
“Staging of Non-Small Cell Lung Cancer with Integrated Positron- Emission Tomography and Computed Topography”
Future directions
Background
Lung cancer (of all types) is the second most common malignancy and the leading cause of cancer death
Lung cancer mortality rate ...
[1571]
Total spondylectomy for en bloc resection of lung cancer invading ...
From [www.thejns-net.org] Last viewed: 07.08.2004
UPERIOR
sulcus or Pancoast tumors are primary lung
tumors invading both the chest wall and vertebral
column and may be characterized by pain, Horner
syndrome, and extention into the bone. Conventionally,
Stage IIIb superior sulcus tumors invading the vertebral
column have been considered unresectable, and the thera-
pies of choice have been radiotherapy alone or radiothera-
py followed by resection. Recent advances in spinal in-
strumentation and wider acceptance of total spondylectomy,
however, make more radical surgical modalities feasible.
Specifically, we have devised a new surgical technique
allowing for the practical en bloc resection of primary lung
cancer invading the chest wall and spinal column. In the
present case we describe the successful outcome after
surgery involving a combination of surgical procedures and
induction therapy.
Case Report
History. This ...
[1572]
Sentinel Node Mapping in Lung Cancer
From [www.annalssurgicaloncology.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1573]
The Interaction of Asbestos and Smoking in Lung Cancer: A Modified ...
From [annhyg.oupjournals.org] Last viewed: 07.08.2004
Web Immagini Gruppi Directory News
Ricerca avanzata Preferenze
Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL
Web
La ricerca di - cache:J_0jblh6RToJ:www.jsnm.org/paper2/37-1/pdf/kaku37106.pdf allintitle: lung cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti:
- Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave.
...
[1574]
Lung Cancer Screening With Helical Computed Tomography in Older ...
From [jama.ama-assn.org] Last viewed: 07.08.2004
lung
cancer
1
Classification of High-Dimensional Lung Cancer Microarray Data
Tsvika Klein
Tufts University
(Joint work with Frederick Crimins, Robert Dimitri, Nathan Palmer and Lenore J. Cowen)
2
Lung Carcinomas
A leading cause of cancer death
Claims ~150,000 lives every year in the US
A better understanding can help:
Design effective drugs
Predict patients survival
Understand lung cancer pathology
3
U95 Probe Microarray
The Human Genome U95 consist of five GeneChip® arrays (Affymetrix)
A powerful tool to analyze human cells and tissues
Expression level of ~ 60,000 genes
~12,000 genes in the first array
4
Microarray Data
5
The Dataset
186 patient ...
[1575]
Lung Cancer Fight Lung Cancer Fight
From [www.gwhospital.com] Last viewed: 07.08.2004
Recent changes in lung cancer
incidence for south Asians
Lucy K Smith, Michael D Peake, Johannes L Botha
In England, the incidence of lung cancer among south
Asians (Indian, Pakistani, and Bangladeshi) is much lower
than in the rest of the population.
1
In the UK, south Asian
population, however, it is the commonest cancer for men
and the second commonest for women.
2
We explored
trends in lung cancer incidence from 1990 to 1999 in
Leicester (22% of residents classified as south Asian in
1991 census).
Participants, methods, and results
We identified cases of lung cancer diagnosed in Leicester
residents between 1 January 1990 and 31 December 1999
from the Trent Cancer Registry. Ethnicity data were not
available for all patients, so we used software assessing
forename and surname to classify patients as ...
[1576]
CT Screening for Early Stage Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1577]
Screening for Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1578]
Transcriptional Profiling of Non-small Cell Lung Cancer Using ...
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1579]
Abbreviated Language Skills Lung Cancer Overdiagnosis Bias
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1580]
The Physiologic Evaluation of Patients With Lung Cancer Being ...
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1581]
New Surgical Options for Elderly Lung Cancer Patients
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1582]
Postoperative Radiotherapy in Radically Resected Non-small Cell ...
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1583]
A Model of Human Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Brochure
More information from http://www.researchandmarkets.com/reports/835
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old
Regimens
Description:
The pharmacological treatment of lung cancer has been dominated by the platinum
analogs for over a decade and with no immediate replacements in sight, they are
expected to play a core role in ling cancer management for the foreseeable future.
However, this is not to say that the lung cancer market will stagnate over the next
seven years. With the emergence of innovative, lower toxicity agents, treatment
outcomes for patients with lung cancer look set to improve dramatically. With new
treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer
provides a detailed examination of the current lung cancer pipeline activities in 7 major
pharmaceutical markets, ...
[1584]
Baseline Findings of a Randomized Feasibility Trial of Lung Cancer ...
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1585]
Survival in Synchronous vs Single Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1586]
Small Cell Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1587]
Impact of Race in Lung Cancer
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1588]
Staging in Lung Cancer: Is 3 cm a Prognostic Threshold in ...
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1589]
Metastatic Lung Cancer Without Regional Lymph Node Swelling
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...
[1590]
A Retrospective Study of Metastatic Lung Cancer Compression of the ...
From [www.chestjournal.org] Last viewed: 07.08.2004
Volume 1, Issue 2
Spring 2001
8 Health Watch
PACE/Queens College
WHPP Health Watch
Spring 2001 Vol. 1 Issue 2
Written, Edited and Compiled by:
Sylvia Kieding, B.A.
Kim Knowlton, MS
Amy Manowitz, MPH
Steve Markowitz, MD
Lyndon Rose, MD, MPH
Other Contributing Authors
David Fry
Mark Griffon
This newsletter has been made possible through funding from the Department
of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512,
awarded to PACE International Union.
In October 2000, the PACE Worker Health Protection
Program conducted the first early lung cancer detection
screenings on the CT scanner mobile unit and held
ribbon-cutting ceremonies at the local union halls of
the three gaseous diffusion sites. The kick-off
ceremonies were a great success thanks to the local union
staff that organized each event. All the events ...